<div id="readability-page-1"><p>Perrigo Company ((PRGO)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Perrigo’s latest earnings call struck a cautiously optimistic tone, blending tangible operational wins with stark near‑term financial pressure. Management highlighted market share gains and cost savings as proof the strategy is working, yet acknowledged that weaker demand, margin compression, and a sizable goodwill impairment are weighing on results. Executives argued these headwinds are temporary and framed 2026 as a back‑half recovery story.</p> <h2>U.S. Store-Brand OTC Gains Underpin Competitive Position</h2> <p>Perrigo underscored notable momentum in U.S. store‑brand over‑the‑counter medicines, reporting a 100 basis point volume share gain in the quarter and 270 basis points in the first quarter overall. Six of seven OTC categories gained share, suggesting the company is taking business from branded rivals even as the broader market softens.</p> <h2>Branded Portfolio in Europe Shows Targeted Strength</h2> <p>In Europe, Perrigo spotlighted branded wins across key franchises, with ellaOne, Jungle Formula, Physiomer, Mederma Cold Sore, and Opill all posting value share gains. Compeed delivered standout seasonal performance, driving Italy to about a 35% share and pushing France toward 36%, reinforcing the strength of the company’s focused brand strategy.</p> <h2>Cost-Savings Program Builds Margin-Recovery Foundation</h2> <p>The operational enhancement program delivered more than $7 million of cost savings in the first quarter and remains on track to generate roughly $60 million to $80 million in 2026. Management expects an additional $20 million to $40 million in 2027, positioning these efficiencies as a key lever to rebuild margins once revenue headwinds ease.</p> <h2>Portfolio Simplification and Balance Sheet Actions</h2> <p>Perrigo completed the sale of its Dermacosmetics business, securing upfront proceeds of about €306 million and signaling plans to use the cash to cut debt. The company also amended its $1 billion revolver, extending maturity to 2031, drew on the facility to repay $421 million of Term Loan A, and maintained capital returns with $40 million in dividends.</p> <h2>EPS Delivery and Reaffirmed Multi-Year Targets</h2> <p>CORE adjusted EPS reached $0.40, while All In adjusted EPS came in at $0.43, with management indicating CORE EPS beat internal expectations despite top‑line pressure. Importantly, Perrigo reaffirmed its full‑year 2026 guidance and reiterated that earnings will be heavily second‑half weighted, with roughly two‑thirds of CORE adjusted EPS expected in the back half.</p> <h2>Innovation and Commercial Execution as Growth Engine</h2> <p>Management emphasized a “360‑degree” innovation approach, combining product launches, store‑brand demand generation, and selective geographic expansion. Roughly 60% of innovation benefits are expected to land in the second half, and Perrigo highlighted that each one‑point increase in U.S. store‑brand household penetration could translate to about $100 million in incremental retail sales.</p> <h2>Revenue Declines Reflect Market and Inventory Pressures</h2> <p>Despite share gains, CORE net sales fell 8.3% year over year, with organic CORE net sales down about 11%, while All In net sales declined 7.2%. The company linked the shortfall mainly to weaker Self Care demand, particularly in cough and cold categories, and to retailers trimming inventory levels.</p> <h2>Headwinds from Cough/Cold Weakness and Destocking</h2> <p>Perrigo quantified that softer cough and cold incidence reduced CORE sales by roughly 3.5%, while retailer inventory destocking added another 3 percentage points of drag. Taken together, these factors accounted for nearly two‑thirds of the net sales decline, reinforcing management’s argument that a large portion of the weakness is cyclical rather than structural.</p> <h2>Margins Under Pressure Across the P&amp;L</h2> <p>Margins deteriorated meaningfully, with CORE adjusted gross margin down 160 basis points to 39.2% and All In gross margin sliding 340 basis points to 37.6%. CORE adjusted operating margin fell 110 basis points to 12.8%, while All In adjusted operating margin dropped 240 basis points to 11.6%, reflecting deleveraging on lower volumes and manufacturing inefficiencies.</p> <h2>Legacy Manufacturing Volume Drag on Earnings</h2> <p>The company flagged carryover manufacturing volume issues as a notable earnings headwind, estimating an unfavorable All In EPS impact of about $0.60 in 2026. Around $0.26 of this drag was already realized in the first quarter, pressuring both volumes and EPS, but management framed the impact as temporary and expected to roll off over time.</p> <h2>Noncash Goodwill Impairment Clouds Reported Results</h2> <p>Perrigo recorded a noncash goodwill impairment of $331 million in the quarter following the reallocation of goodwill to new reporting units. While executives stressed that the charge does not affect cash flows or liquidity, it is a sizeable hit to reported earnings and underscores the challenges baked into the company’s legacy asset base.</p> <h2>Working Capital and Cash Flow Remain Stress Points</h2> <p>Operating cash flow was a negative $114 million in the first quarter, a $49 million deterioration versus the prior year, with management noting that the first quarter is typically the peak period for cash usage. Total debt stood at $3.6 billion, and although divestiture proceeds and cost savings are expected to improve leverage over time, the balance sheet remains a key area for investors to monitor.</p> <h2>Macro and Market Weakness Across U.S. and Europe</h2> <p>Underlying market trends were unsupportive, with the U.S. OTC market down roughly 4.1% in value and 2.1% in volume over the period. European markets fared similarly, falling about 3.7% in value and 4.4% in volume, as soft cough and cold seasons and broader macroeconomic pressures weighed on consumer health spending.</p> <h2>Guidance Framed as a Second-Half Recovery Story</h2> <p>Forward‑looking commentary centered on a back‑half‑loaded recovery, with management reiterating that only about 30% to 35% of CORE adjusted EPS is expected in the first half and 65% to 70% in the second half of the year. While near‑term guidance reflects margin pressure from volume declines, manufacturing variance, and market softness, the company is banking on innovation, cost savings, and normalized demand to restore growth and profitability into 2026.</p> <p>Perrigo’s earnings call painted a story of a company executing commercially but wrestling with cyclical and structural headwinds that are temporarily obscuring progress. Investors are being asked to look through weak current sales, margin compression, and heavy leverage in anticipation of a stronger second half and a more profitable 2026, making execution on innovation and cost discipline critical watchpoints.</p></div>

PRGO

<p>Perrigo Company (PRGO) held its Q1 earnings call, highlighting a mix of operational successes and financial pressures. The company reported market share gains in U.S. store-brand OTC medicines but faced challenges from weaker demand and margin compression. Perrigo's operational enhancements yielded over $7 million in cost savings, with expectations of $60-$80 million by 2026. Despite a decline in CORE net sales by 8.3% year-over-year, management remains optimistic about a recovery in the second half of 2026, reaffirming its full-year guidance. A noncash goodwill impairment of $331 million impacted reported earnings, but cash flow concerns persist.</p>

Perrigo Earnings Call Balances Progress and Pressure